Sky Labs Champions Innovative Research With American Heart Association's Clinical Hypertension Award Support
Sky Labs Champions Innovative Research with American Heart Association's Clinical Hypertension Award Support
Sky Labs, a pioneering healthcare company based in South Korea, has made headlines by announcing its endorsement of the Established Investigator Award for Clinical Hypertension, organized by the American Heart Association (AHA). This significant move, which took place on March 12, 2026, signifies a robust commitment to advancing hypertension research on an international scale.
The collaboration builds on a memorandum of understanding that was signed with the AHA in September 2025. This agreement sets the stage for Sky Labs to provide substantial financial backing to the award, specifically targeting three distinguished researchers with noteworthy contributions to hypertension research over the three-year period from 2026 to 2028. The total funding allocated to this initiative is approximately $90,000, which will cover annual remuneration for the selected investigators and all associated costs necessary to facilitate the awarding process.
Eligibility for this prestigious award is granted to members of the AHA's Scientific Council on Hypertension. This criterion ensures that the recognition is given to researchers who have demonstrated significant expertise and commitment to combating hypertension through their work.
Jack Byunghwan Lee, CEO of Sky Labs, expressed enthusiasm about this collaboration: “It is a tremendous honor for us to support the American Heart Association and contribute to global research outcomes in hypertension. We will continue to strengthen clinical research to validate blood pressure management solutions while advancing the R&D efforts that back these initiatives.” This statement underscores the emphasis Sky Labs places on fostering a research environment that facilitates impactful and innovative developments in healthcare.
About Sky Labs
Founded in September 2015, Sky Labs specializes in artificial intelligence-driven healthcare solutions, particularly focusing on chronic diseases. One of its flagship products, CART, is the world's first medical wearable blood pressure monitoring ring, which has garnered attention for its innovative approach to patient care.
In 2020, Sky Labs launched its initial CART device aimed at monitoring atrial fibrillation utilizing heart signals obtained from optical sensors. Since then, the company has continuously expanded its technological capabilities. Notably, in 2023, it secured medical device approval for the CART BP Pro, developed for 24-hour blood pressure monitoring. This device was further recognized by the Health Insurance Review and Assessment Service (HIRA) in 2024, allowing it to be prescribed across hospitals and clinics in South Korea.
Sky Labs didn't stop there; in September 2025, the company introduced the consumer-oriented CART BP, a blood pressure monitoring ring made available through online retail channels. This expansion into the consumer market marks a significant milestone for the company's growth trajectory and commitment to making healthcare technology accessible to all.
As Sky Labs continues to innovate and partner with esteemed organizations like the AHA, the pathways for groundbreaking research and advancements in hypertension management remain wide open. Future developments and findings could pave the way for improved patient outcomes, which is the ultimate goal of this innovative healthcare company.
For more information about Sky Labs and its initiatives, visit Sky Labs Official Website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.